NYSE: WRBYWarby Parker Inc Stock
$15.80+0.34 (+2.2%)
Updated Apr 29, 2025
WRBY Price
$15.80
Fair Value Price
N/A
Market Cap
$1.91B
52 Week Low
$11.66
52 Week High
$28.68
P/E
-92.94x
P/B
5.62x
P/S
3.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$771.32M
Earnings
-$20.39M
Gross Margin
55.3%
Operating Margin
-3.9%
Profit Margin
-2.6%
Debt to Equity
0.99
Operating Cash Flow
$99M
Beta
1.88
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
WRBY Overview
Warby Parker Incorporated offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray. The company also offers eye exams and vision tests directly to consumers through its retail stores and website. Warby Parker operates160 retail stores in the U.S. and Canada. Known as JAND Inc. until 2021, Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine WRBY's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
WRBY
Ranked#17 of 42
Ranked#17 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $66.40 | B | |
| $4.92 | B | |
| $206.44 | B |
Be the first to know about important WRBY news, forecast changes, insider trades & much more!
WRBY News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how WRBY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WRBY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
WRBY is poor value based on its book value relative to its share price (5.62x), compared to the US Medical Instruments & Supplies industry average (3.73x)
P/B vs Industry Valuation
WRBY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more WRBY due diligence checks available for Premium users.
Valuation
WRBY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-92.94x
Industry
40.25x
Market
29.19x
WRBY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.62x
Industry
3.73x
WRBY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WRBY's financial health
Profit margin
Revenue
$190.6M
Net Income
-$6.9M
Profit Margin
-3.6%
WRBY's Earnings (EBIT) of -$30.11M... subscribe to Premium to read more.
Interest Coverage Financials
WRBY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$676.5M
Liabilities
$336.4M
Debt to equity
0.99
WRBY's short-term assets ($326.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WRBY's short-term assets ($326.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WRBY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WRBY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$19.9M
Investing
-$17.7M
Financing
$1.2M
WRBY's operating cash flow ($98.74M)... subscribe to Premium to read more.
Debt Coverage Financials
WRBY vs Medical Stocks
Warby Parker Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.